EXPLORE!

FDA: Clarithromycin increases risk of heart problems in patients with heart disease

  1580 Views

eMediNexus    23 February 2018

In a drug safety communication, the US FDA has advised caution before prescribing the antibiotic clarithromycin (Biaxin) to patients with heart disease because of a potential increased risk of heart problems or death that can occur years later. It also advises prescribers to consider using other antibiotics in such patients. This advisory follows the CLARICOR trial, which found an unexpected increase in deaths among patients with coronary heart disease who received a two-week course of clarithromycin that became apparent after patients had been followed for one year or longer.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.